ArticleNeuroImage. Clinical2022
Periventricular gradient of T
Article in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Periventricular gradient of normal-appearing white matter in normal aging and multiple neurological diseases.Journal of advanced research · 2026Article
- Normative THuman brain mapping · 2026Article
- Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- SARS-CoV-2 Is Linked to Brain Volume Loss in Multiple Sclerosis.Annals of clinical and translational neurology · 2025Article
- Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes.AJNR. American journal of neuroradiology · 2024Article
- Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.Journal of neurology · 2024Article
- Inhomogeneous magnetization transfer (ihMT) imaging reveals variable recovery profiles of active MS lesions according to size and localization.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Periventricular and juxtacortical characterization of UManitoba-JHU functionally defined human white matter atlas networks.Frontiers in human neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePathology in multiple sclerosis is not homogenously distributed. Recently, it has been shown that structures adjacent to CSF are more severely affected. A gradient of brain tissue involvement was shown with more severe pathology in periventricular areas and in proximity to brain surfaces such as the subarachnoid spaces and ependyma, and hence termed the "surface-in" gradient. Here, we study whether (i) the surface-in gradient of periventricular tissue alteration measured by T
methodsForty-seven patients with early multiple sclerosis, 52 with progressive multiple sclerosis, and 92 healthy controls were included in the study. Isotropic 3D T
resultsPatients with early and progressive multiple sclerosis demonstrated a periventricular gradient of T
conclusionOur results suggest that the surface-in white matter gradient of tissue alteration is detectable with T1 relaxometry and is already present at clinical disease onset. The periventricular gradients correlate with clinical disability. The periventricular gradient in normal-appearing white matter may thus qualify as a promising biomarker for monitoring of disease activity from an early stage in all phenotypes of multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.